Health

STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in China

A few of the largest pharmaceutical companies have told a Congressional committee that they do not plan to start new clinical trial sites in the Xinjiang region of China or at hospitals affiliated with the Chinese military.

✦ Extractive summary — built from the sources' own reporting•From 1 source•1 min read•Updated November 20, 2026, 12:00 AM UTC
Key points
  • The disclosure was made by the House Select Committee on China, which last June opened investigations into five companies — Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb — over concerns about intellectual property exposure, military entanglements, and ethical standards at trial sites in sensitive regions of the country.
  • Continue to STAT+ to read the full story….

All five companies indicated they would not initiate new clinical studies at sites linked to the People’s Liberation Army, which is the military wing of the Chinese Communist Party.

In letters sent to the drugmakers, the House committee noted rising concern over the possibility of security risks.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Advertisement

Every article behind this summary — 1 article from 1 outlet